Mono-iodoacetate Injection
Mono-iodoacetate Injection - Related Videos
08:09
Osteoarthritis Pain Model Induced by Intra-Articular Injection of Mono-Iodoacetate in Rats
0 Views •
Cited by 28 •
2020
This study describes the method of intra-articular injection of mono-iodoacetate in rats and discusses the resulting pain-related behaviors and histopathological changes, which provide references for future applications.
04:37
Detection and Quantification of Mono-Rhamnolipids and Di-Rhamnolipids Produced by Pseudomonas aeruginosa
0 Views •
Cited by 4 •
2024
Pseudomonas aeruginosa produces the rhamnolipid biosurfactants. Thin-layer chromatography detects and determines the proportion of mono- and di-rhamnolipids produced by each strain. Quantification of total rhamnolipids involves assessing rhamnose equivalents present in these biosurfactants extracted from the culture supernatants using the orcinol method.
06:53
A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
0 Views •
Cited by 6 •
2015
MicroRNAs play crucial roles in the brain and are potential targets for modeling neuro-degeneration. However, perturbing miRNA levels is challenging due to the short length of miRNA and inaccessibility of the brain tissue. This video presents a method for antagomir design and brain specific delivery using a neuropeptide in mice.
09:06
Intra-lymph Node Injection of Biodegradable Polymer Particles
0 Views •
Cited by 45 •
2014
Lymph nodes are the immunological tissues that orchestrate immune response and are a critical target for vaccines. Biomaterials have been employed to better target lymph nodes and to control delivery of antigens or adjuvants. This paper describes a technique combining these ideas to inject biocompatible polymer particles into lymph nodes.
08:28
Zebrafish Brain Ventricle Injection
0 Views •
Cited by 72 •
2009
After neural tube formation, the neuroepithelium constricts and folds while the tube fills with embryonic cerebrospinal fluid (eCSF) to form the embryonic brain ventricles. We developed this ventricle injection technique to better visualize the fluid filled space in contrast to the neuroepithelial shape in a live embryo.
FAQs
The central molecular event is inhibition of glyceraldehyde-3-phosphate dehydrogenase in chondrocytes. This blocks a key step in glycolysis, limiting the cells’ ability to generate energy. Energy disruption makes chondrocyte survival unsustainable and initiates downstream tissue injury. This mechanism links the injected chemical to the cellular changes that drive cartilage degeneration in the affected joint.
Chondrocyte death removes cells that help maintain cartilage, so cellular loss contributes to progressive cartilage degeneration. The resulting joint damage is accompanied by inflammation and pain-related behavior. Because these changes occur together, the model allows researchers to examine how cellular injury is connected with structural deterioration and nociceptive responses rather than assessing pain independently from tissue pathology.
Intra-articular delivery concentrates the chemical effect within a selected joint, creating a localized injury rather than describing a generalized disease state. This localization provides experimental control over where damage develops and supports focused examination of joint tissues, pain-related behavior, and functional impairment. The approach therefore connects a defined site of injury with measurable disease-related consequences.
A typical workflow begins with intra-articular administration to induce joint damage, followed by evaluation of the resulting biological and behavioral changes. Researchers can examine cartilage degeneration, inflammation, pain-related behavior, nociceptive pathways, structural changes, and functional impairment. The controlled sequence helps relate the initial joint insult to later outcomes relevant to degenerative joint disease.
The model can provide complementary information at cellular, structural, pathway, and behavioral levels. Investigators may study chondrocyte injury, cartilage degeneration, inflammation, nociceptive pathways, pain-related behavior, and impaired function. Considering these outcomes together helps characterize both disease mechanisms and the observable consequences of joint damage, strengthening interpretation of experimental treatment effects.
Researchers use this model before clinical investigation to evaluate analgesic, anti-inflammatory, and potential disease-modifying treatments. Analgesic testing focuses on pain-related outcomes, whereas anti-inflammatory studies address inflammatory changes; disease-modifying investigations consider whether treatment may influence the underlying degenerative process. Its controlled joint injury makes it suitable for comparing treatment effects with defined pathological and functional outcomes.